Advertisement

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Advertisement

Advertisement




Dec
13
Today In Oncology
Adding Tucatinib to First-Line Maintenance Therapy Delays Disease Progression in HER2-Positive Metastatic Breast Cancer
Mobile Health Intervention Offers Tailored Support for Adolescent and Young Adult Breast Cancer Survivors
Can Multimodal AI Models Predict Distant Recurrence Risk in Patients With Early Breast Cancer
Doublet Therapy Yields Higher Response Rates and Fewer Complications Than Standard Induction in AML
Ianalumab Plus Eltrombopag Extends Time to Treatment Failure in ITP
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo